Latest Reimbursement News

Control Bionics reports a strong start to FY26 with nearly 10% revenue growth, expanded US reimbursement coverage, and advancing commercialization of its NeuroNode and NeuroStrip technologies.

4DMedical Limited has secured FDA clearance and immediate Medicare reimbursement for its groundbreaking CT – VQ™ lung imaging technology, accelerating commercial adoption across the US, Brazil, and Australia.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.

Novonix Limited has achieved its first mass production of industrial-grade synthetic graphite and secured significant funding, advancing its position in North America's battery materials supply chain.

ImpediMed Limited reported a record A$3.6 million quarterly revenue and expanded its US hospital footprint with over 600 SOZO units installed. The launch of SOZO Pro targets new heart failure markets, while reimbursement coverage accelerates across US states.

Dimerix Limited reports solid progress in its Phase 3 trial for DMX-200 targeting rare kidney disease FSGS, backed by orphan drug status in Japan and a robust cash position. The company prepares to engage the FDA on new data supporting regulatory approval.

Ansell Limited delivered a robust FY25 performance driven by organic growth, successful Kimberly-Clark PPE integration, and productivity gains, while advancing sustainability goals and managing trade headwinds.

Proteomics International Laboratories has secured ISO 15189 certification and launched PromarkerD and PromarkerEso nationally in Australia, while advancing US reimbursement pathways and preparing for leadership transition.

Artrya Limited has secured FDA clearance for its Salix Coronary Plaque module and raised $80 million to fuel its U.S. commercial expansion, marking a pivotal step in its transition from development to revenue generation.

Boom Logistics reports steady revenue growth and significant capital expenditure cuts in Q1 FY26, while advancing a share buyback and navigating leadership changes.

Woodside Energy Group has sealed a strategic partnership with US infrastructure giant Williams, selling stakes in Louisiana LNG and Driftwood Pipeline for $378 million, accelerating the project’s path to first LNG in 2029.

Lumos Diagnostics reported steady quarterly revenue with a 300% surge in product sales, driven by its flagship FebriDx® test. The company inked a landmark US$317 million exclusive U.S. distribution agreement and awaits FDA feedback on its CLIA waiver application.